Humana Pulls Back The Curtain On Planning For 2027 MA Bids

Humana reported Q1 profit of $1.19 billion and revenue of $39.6 billion, both ahead of analyst forecasts, while reaffirming 2026 EPS guidance of at least $9 and a 2026 medical loss ratio of 92.75%. The company expects Medicare Advantage membership to rise about 25% versus 2025, but warned that weaker Star Ratings could pressure quality bonus payments, revenues, operating results, and cash flows. Management said rising medical costs mean benefit adjustments may be needed to reach a stable margin by 2028.

Analysis

The key implication is that MA economics are shifting from a pricing story to a benefit-design and utilization-management story. That favors insurers with tighter local provider control, more diversified benefit menus, and the ability to trade away low-value richness without triggering disproportionate disenrollment. Humana’s comments suggest the next margin leg is more likely to come from product redesign and network steering than from headline premium increases, which should widen dispersion across MA carriers over the next 2-4 bid cycles.

The second-order loser is any player whose membership mix is more reliant on value-rich benefit packages or who lacks the granularity to adjust market-by-market. The risk is not just lower enrollment growth; it is that benefit trimming can degrade the risk pool by disproportionately retaining higher-acuity members who value richer access, pushing MLR higher before pricing re-rates. That creates a lagged earnings squeeze that may not fully show up until late 2026 into 2027, especially if CMS funding remains only modestly supportive.

The legal overhang matters because it can delay confidence in quality bonus recovery and keep the stock pinned even if core operating trends stabilize. Near term, the setup is asymmetric: shares can rally on beat-and-raise execution, but multiple expansion likely requires evidence that 2027 bids preserve membership without sacrificing margin. If star ratings deterioration proves less severe than feared, the market could quickly re-rate the stock because the current discount already embeds a fair amount of downside from bonus pressure and higher acuity costs.

Key Decisions for Investors

• Maintain a tactical underweight on HUM into the 2027 bid season; use any 5-8% post-earnings strength to add via 1-3 month put spreads, targeting downside from star-ratings uncertainty and benefit-reset risk.
• Pair trade: long UNH / short HUM for the next 2 quarters. Thesis: UNH has more control over pricing, care delivery, and mix, while HUM faces a more visible margin repair path and greater legal/ratings overhang.
• Buy optionality on a diversified managed-care basket versus HUM singles: long XLV calls or HUM put spreads into late-2026 catalysts, since the main risk is a sector-wide repricing if MA funding improves more than expected.
• For investors who need MA exposure, rotate toward names with stronger local/provider integration and less dependence on benefit richness; avoid adding to pure-play MA exposure until 2027 bid outcomes and star ratings are clearer.
• Set a review trigger around the next annual bid/Stars update: if HUM can show stable member retention with no incremental MLR deterioration, cover shorts quickly because the stock could re-rate sharply on reduced uncertainty.